Mammalian Cell Culture CDMO Services In India Serving Globally
Scalable mammalian cell culture solutions advancing mAbs and biopharmaceuticals from gene-to-clone development through commercial drug substance manufacturing.
Measurable Outcomes for Every Partner
End-to-End Mammalian Biomanufacturing & Drug Substance Services
At Shilpa Biologicals, we deliver end-to-end mammalian cell culture contract development and manufacturing organization (CDMO) services tailored for global pharmaceutical and biotechnology innovators. Operating out of our advanced biomanufacturing facility in Dharwad, Karnataka, India, Shilpa Biologicals provides flexible, cGMP-compliant solutions across all phases of biologics drug substance manufacturing.
Whether your molecule requires early-stage gene-to-cell line development, high-titer process optimization, or large-scale clinical and commercial production, our integrated team combines host cell expression technologies with single-use bioreactor systems to guarantee yield, consistency and regulatory speed.
Our Global Regulatory Certifications
Complete Gene-to-Market Mammalian Biomanufacturing Platforms
Gene & Clone Development
CHO / HEK293 platforms
Upstream Bioprocessing
50L to 2,000L single-use
Downstream Purification
Dual independent DSP streams
Analytical & cGMP Drug Substance
Characterization, release & commercial supply
High-Yield Expression Platforms & Host Systems
Selecting the correct host cell line is foundational to achieving high volumetric productivity and target critical quality attributes (CQAs). We support a wide array of mammalian expression systems:
- CHO Cell Line Platforms: Industry-standard CHO-S, CHO-K1 and CHO GS host systems engineered for metabolic stability, rapid growth and high expression titers (≥5 g/L).
- Alternative Expression Systems: Specialized expression utilizing HEK293 (human embryonic kidney) and SF9 (insect cell culture via baculovirus) for difficult-to-express proteins and viral vectors.
- Proprietary Construct Engineering: Tailored promoter selection, codon optimization, vector design and stable clone isolation to maximize specific productivity (qₚ).
Scalable Upstream Process Development
Our upstream biomanufacturing suites utilize high-throughput micro-scale platforms to de-risk scale-up:
- High-Throughput Screening: Rapid media and feed screening using Ambr® 15mL Micro Bioreactors and shake-flask screening arrays.
- Process Scale-Down Models: Bench-top 2L and 10L glass bioreactors used to establish design spaces through Quality by Design (QbD) and Design of Experiments (DoE) principles.
- Flexible Process Modes: Robust execution across Fed-Batch, High-Density (HD) Fed-Batch and continuous Perfusion modes for sustained cell viability and high product yields.
Looking to scale your CHO-based biopharmaceutical from bench to commercial scale?
Shilpa Biologicals offers tailored cGMP biomanufacturing solutions designed for USFDA and EMA compliance.
Schedule an Expert MeetingMammalian Drug Substance Manufacturing Process
Clone & Cell Banking
Vector design, CHO-K1/GS transfection, clone isolation, cGMP MCB/WCB production.
Upstream Seed Train & Production
Expansion via shake flasks to RM bioreactors into 50L to 2,000L single-use bioreactors.
Harvest & Clarification
Primary cell separation using depth filtration (9.6 m² capacity per stream).
Downstream Purification (DSP)
Multi-column chromatography (up to 600 L/Hr capacity) and Tangential Flow Filtration (TFF, 0.5 to 5 m²).
Viral Clearance & Safety
Low pH/detergent viral inactivation + orthogonal nanofiltration (ICH Q5A).
Formulation & Cold Chain
Final UF/DF formulation, bulk storage in walk-in cold environments.
World-Class Regulatory Approvals, Quality Systems & Compliance
Shilpa Biologicals operates state-of-the-art biomanufacturing facilities governed by an integrated Quality Management System (QMS). Our infrastructure operates under strict CDSCO regulations, holds WHO GMP certification and is engineered to maintain compliance with USFDA, EMA, ANVISA and PICS standards.
- Quality by Design (QbD): Analytical Method Development (AMD) and Quality Control (QC) platforms ensure that Critical Quality Attributes (CQAs) are systematically measured and controlled throughout production.
- Analytical Testing Architecture: In-house testing capabilities include SEC-HPLC, CEX/AEX, LC-MS/MS glycan mapping, host cell residual DNA qPCR, and cell-based functional potency assays.
- Regulatory Filing Assistance: Regulatory affairs teams provide end-to-end support for IND (Investigational New Drug) and BLA (Biologics License Application) dossier compilation.
Mammalian CDMO : Frequently Asked Questions
What mammalian host cell lines does Shilpa Biologicals offer for CDMO projects?
What is the single-use bioreactor capacity for mammalian manufacturing at Shilpa Biologicals?
Can Shilpa Biologicals handle continuous perfusion biomanufacturing for mammalian cell culture?
How does Shilpa Biologicals ensure viral safety in mammalian biologics manufacturing?
Does Shilpa Biologicals support both Drug Substance (DS) and Drug Product (DP) fill-finish?
Mammalian Cell Culture CDMO in India: Scalable Biomanufacturing for Global Pharma Partners
Mammalian Cell Culture CDMO Services in India by Shilpa Biologicals
Shilpa Biologicals is a fully integrated mammalian cell culture CDMO in India, delivering end-to-end biologics drug substance manufacturing services to pharmaceutical and biotechnology companies across the globe. Operating from an advanced cGMP biomanufacturing facility in Dharwad, Karnataka, Shilpa Biologicals provides scalable mammalian manufacturing solutions spanning gene-to-cell line development, upstream and downstream bioprocessing, drug substance production and integrated drug product fill-finish. Our mammalian CDMO services support partners across the United States, European Union, Canada, Brazil, Japan and other regulated markets with the technical rigour and regulatory alignment that global submissions demand.
What is Mammalian Cell Culture CDMO?
A mammalian cell culture CDMO is a contract development and manufacturing organization that specializes in developing and producing biopharmaceutical drug substances using mammalian expression systems such as CHO (Chinese Hamster Ovary), HEK293 and other host cell platforms. Mammalian cell culture manufacturing is critical for producing complex therapeutic proteins including monoclonal antibodies, bispecific antibodies, Fc-fusion proteins, biosimilars and recombinant proteins that require post-translational modifications such as glycosylation for clinical and commercial efficacy.
Shilpa Biologicals operates as a mammalian CDMO in India, providing these specialized cell culture manufacturing capabilities to global innovators who require cGMP mammalian drug substance production backed by robust analytical characterization and regulatory filing support.
Why Global Companies Choose Mammalian CDMO Services in India
India has established itself as a strategic destination for mammalian biopharmaceuticals manufacturing. International pharmaceutical companies increasingly partner with Indian biologics CDMOs in India for mammalian cell culture for biopharmaceutical production for the following reasons:
- Scientific Talent Pool: India provides access to highly trained bioprocess engineers, cell biologists and analytical scientists with deep expertise in mammalian cell culture manufacturing and upstream and downstream bioprocessing.
- Cost-Competitive Infrastructure: Mammalian biomanufacturing in India delivers significant cost advantages compared to US and European facilities without compromising on cGMP compliance, technology platforms or product quality.
- Regulatory Readiness: Leading biologics CDMOs in India such as Shilpa Biologicals operate under CDSCO regulations and maintain compliance alignment with USFDA, EMA, ANVISA and PIC/S standards, enabling seamless regulatory submissions in global markets.
- Integrated Capabilities: Shilpa Biologicals provides a fully backward-integrated mammalian CDMO platform in India covering cell line development through commercial drug substance manufacturing and fill-finish, eliminating multi-vendor coordination.
- Speed to Clinic and Market: Streamlined workflows and dedicated project teams at Shilpa Biologicals accelerate timelines from process development through clinical and commercial drug substance release.
Backed by Decades of Pharmaceutical Excellence
Shilpa Biologicals is a subsidiary of Shilpa Medicare Limited, a publicly listed pharmaceutical company with over three decades of proven success in drug development, regulatory approvals and global supply across 50+ countries. This parentage provides Shilpa Biologicals with access to established quality management systems, deep regulatory expertise and robust operational infrastructure that underpin every mammalian CDMO engagement.
As the dedicated biologics arm of the Shilpa group, Shilpa Biologicals brings this legacy of pharmaceutical excellence to the mammalian biopharmaceuticals space, combining heritage and innovation to serve global CDMO partners.
Mammalian Biomanufacturing Capabilities at Shilpa Biologicals in India
Shilpa Biologicals operates a purpose-built mammalian biomanufacturing facility in Dharwad, India, equipped with single-use bioreactor technology and independent drug substance manufacturing streams. Core capabilities for mammalian cell culture manufacturing include:
- Cell Line Development: CHO-S, CHO-K1, CHO GS, HEK293 and SF9 host systems with custom vector engineering, clone selection and cGMP Master Cell Bank (MCB) production.
- Upstream Bioprocessing: Ambr® 15mL micro bioreactors for high-throughput screening, bench-top 2L and 10L glass bioreactors for process development and production-scale 50L, 200L, 1000L and 2000L single-use bioreactors supporting Fed-Batch and continuous Perfusion modes.
- Downstream Purification: Automated multi-step chromatography (Protein A/G, AEX/CEX, HIC) with strict pre-viral and post-viral segregation across dual independent 2,000 sqm drug substance streams.
- Drug Substance Capacity: 8,000 Liters of operational mammalian drug substance capacity with planned expansion to 16,000 Liters.
- Integrated Fill-Finish: EU GMP-approved automated drug product operations including isolator-based RTU combi lines and high-speed vial filling across 2R to 100R formats.
Regulatory Approvals and Quality Compliance
Shilpa Biologicals operates under an integrated Quality Management System (QMS) designed to meet the highest international regulatory standards for mammalian biologics manufacturing. Our biomanufacturing facility maintains the following certifications and compliance alignments:
- WHO GMP Certified: Active WHO Good Manufacturing Practice certification for the biologics manufacturing facility.
- CDSCO Regulated: Operating under the Central Drugs Standard Control Organisation, India's national regulatory authority.
- USFDA Aligned: Facility infrastructure and quality systems engineered for United States Food and Drug Administration compliance.
- EMA Aligned: Drug substance manufacturing processes designed for European Medicines Agency submission readiness.
- ANVISA Aligned: Compliance alignment with Brazil's Agencia Nacional de Vigilancia Sanitaria for Latin American market access.
- PIC/S Standards: Pharmaceutical Inspection Co-operation Scheme GMP standards maintained across all manufacturing operations.
- EU GMP Approved (Fill-Finish): European Union GMP approval held specifically for the drug product fill-finish line.
- 21 CFR Part 11 Compliant: Manufacturing equipment and computerized systems qualified to support data integrity requirements including user access controls, audit trails and electronic data management.
In-house analytical capabilities including SEC-HPLC, LC-MS/MS glycan mapping, host cell residual DNA qPCR and cell-based potency assays support comprehensive drug substance characterization at every stage of the manufacturing process. Regulatory affairs teams at Shilpa Biologicals provide end-to-end support for IND and BLA dossier compilation, helping global partners navigate regulatory pathways across the US, EU, Brazil, Japan and other target markets.
Partner with Shilpa Biologicals for Mammalian Cell Culture Manufacturing in India
For pharmaceutical and biotechnology companies seeking a reliable mammalian CDMO partner in India with global regulatory alignment, Shilpa Biologicals delivers the technical depth, facility scale and quality infrastructure required to advance biologics programs from early development through commercial supply. Whether the requirement is mammalian cell culture for biopharmaceutical production at clinical scale or full commercial biologics drug substance manufacturing, our integrated biomanufacturing platform in India is designed to accelerate your path to global markets. Contact Shilpa Biologicals to discuss your mammalian CDMO requirements.
